Skip to main content

Soligenix, Inc.

SNGX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000812796

No open-market purchases or sales by Soligenix, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $369.6K in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Soligenix, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of SNGX: Q1 2021 compared with Q2 2021
MeasureQ1 2021Of which not filed for Q2 2021Q2 2021Change
Holders351340
Shares3.41M20.8K4.14M+744.9K (+22.0%)
Value$5.22M$32.0K$4.59M−$594.9K (−11.5%)

1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (6)

Institutions that held Soligenix, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to SNGX in Q2 2021
InstitutionSharesValue% of portfolio
Renaissance Technologies LLC296,111$329.0K0.00%
Goldman Sachs Group Inc54,006$60.0K0.00%
State Street Corp44,870$50.0K0.00%
Two Sigma Advisers, LP26,300$29.0K0.00%
Albion Financial Group475$1.00K0.00%
FMR LLC1$00.00%

Sold out (6)

Institutions that held Soligenix, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.

Institutions that sold out of SNGX in Q2 2021
InstitutionShares, Q1 2021Value, Q1 2021
Gsa Capital Partners LLP136,502$209.0K
California Public Employees Retirement System126,170$193.0K
Meridian Wealth Partners, LLC5,050$8.00K
UBS Group AG1,988$3.00K
American Portfolios Advisors1,240$1.90K
Royal Bank of Canada15$0

Not filed for Q2 2021 yet (1)

Institutions that held Soligenix, Inc. at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SNGX in Q1 2021 that haven't filed for Q2 2021
InstitutionShares, Q1 2021Value, Q1 2021
Money Concepts Capital Corp20,750$32.0K